Ramez Eskander

Title(s)Clinical Professor, Ob/Gyn & Reproductive sciences
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Websites

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors. Gynecol Oncol. 2024 Jun 03; 187:241-248. Aisagbonhi O, Ghlichloo I, Hong DS, Roma A, Fadare O, Eskander R, Saenz C, Fisch KM, Song W. PMID: 38833993.
      View in: PubMed   Mentions:    Fields:    
    2. ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass, No Acute Symptoms: 2023 Update. J Am Coll Radiol. 2024 Jun; 21(6S):S79-S99. Expert Panel on GYN and OB Imaging, Patel-Lippmann KK, Wasnik AP, Akin EA, Andreotti RF, Ascher SM, Brook OR, Eskander RN, Feldman MK, Jones LP, Martino MA, Patel MD, Patlas MN, Revzin MA, VanBuren W, Yashar CM, Kang SK. PMID: 38823957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell. 2024 Jun 20; 187(13):3390-3408.e19. Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, Burns MJ, McRae HM, Stevenson BT, Coakley KE, Ho J, Gastelum KB, Bell JC, Jones AC, Eskander RN, Dykhuizen EC, Shadel GS, Kaech SM, Hargreaves DC. PMID: 38754421; PMCID: PMC11193641.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    4. Top advances of the year: Uterine cancer. Cancer. 2024 Jul 15; 130(14):2409-2412. Erickson BK, Slomovitz B, Powell M, Eskander RN. PMID: 38620054.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Recent Therapeutic Advances in Gynecologic Oncology: A Review. Cancers (Basel). 2024 Feb 13; 16(4). Wilson EM, Eskander RN, Binder PS. PMID: 38398161; PMCID: PMC10887183.
      View in: PubMed   Mentions:
    6. Revisiting immunotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2024 Jan-Feb; 22(1):28-30. Eskander RN. PMID: 38294738.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks. Surg Oncol Clin N Am. 2024 Apr; 33(2):279-291. Nishizaki D, Eskander RN. PMID: 38401910.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy. Mol Cancer Ther. 2023 Nov 01; 22(11):1352-1362. Jou J, Kato S, Miyashita H, Thangathurai K, Pabla S, DePietro P, Nesline MK, Conroy JM, Rubin E, Eskander RN, Kurzrock R. PMID: 37619986.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol. 2023; 13:1258228. Eskander RN, Moore KN, Monk BJ, Herzog TJ, Annunziata CM, O'Malley DM, Coleman RL. PMID: 37916177; PMCID: PMC10616588.
      View in: PubMed   Mentions: 3  
    10. PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply. N Engl J Med. 2023 Aug 31; 389(9):867-868. Eskander RN. PMID: 37646696.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review. JAMA Oncol. 2023 06 01; 9(6):851-859. Richardson DL, Eskander RN, O'Malley DM. PMID: 37079311.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    12. Prevention of venous thromboembolism in patients with cancer. BMJ. 2023 06 01; 381:e072715. Guntupalli SR, Spinosa D, Wethington S, Eskander R, Khorana AA. PMID: 37263632.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    13. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Int J Gynecol Cancer. 2023 04 03; 33(4):504-513. Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, Slomovitz B, Elvin JA, Eskander RN. PMID: 36750267; PMCID: PMC10086481.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    14. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 08; 388(23):2159-2170. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. PMID: 36972022; PMCID: PMC10351614.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
    15. Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy. Res Sq. 2023 Feb 16. Jou J, Kato S, Miyashita H, Thangathurai K, Pabla S, DePietro P, Nesline M, Conroy J, Rubin E, Eskander R, Kurzrock R. PMID: 36824739; PMCID: PMC9949233.
      View in: PubMed   Mentions:
    16. Immunotherapy treatment landscape for patients with endometrial cancer: current evidence and future opportunities. Clin Adv Hematol Oncol. 2023 Jan; 21(1):27-34. Hom-Tedla M, Eskander RN. PMID: 36638353.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. NPJ Precis Oncol. 2022 Sep 22; 6(1):67. Louie BH, Kato S, Kim KH, Lim HJ, Okamura R, Eskander RN, Botta G, Patel H, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 36138116; PMCID: PMC9500013.
      View in: PubMed   Mentions: 2  
    18. Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer. J Comput Assist Tomogr. 2022 Sep-Oct 01; 46(5):707-715. Ghani MA, Liau J, Eskander R, Mell L, Yusufaly T, Obrzut S. PMID: 35995483; PMCID: PMC9474655.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Practice changing cervical cancer clinical trials. Gynecol Oncol. 2022 06; 165(3):410-412. Pothuri B, Eskander RN, Randall LM, O'Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ. PMID: 35461731.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond). 2022; 2:29. Hinestrosa JP, Kurzrock R, Lewis JM, Schork NJ, Schroeder G, Kamat AM, Lowy AM, Eskander RN, Perrera O, Searson D, Rastegar K, Hughes JR, Ortiz V, Clark I, Balcer HI, Arakelyan L, Turner R, Billings PR, Adler MJ, Lippman SM, Krishnan R. PMID: 35603292; PMCID: PMC9053211.
      View in: PubMed   Mentions: 35  
    21. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precis Oncol. 2022 01; 6:e2000508. Charo LM, Eskander RN, Sicklick J, Kim KH, Lim HJ, Okamura R, Lee S, Subramanian R, Schwab R, Shatsky R, Plaxe S, Kato S, Kurzrock R. PMID: 35005995; PMCID: PMC8769125.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    22. Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics. J Nucl Med. 2022 07; 63(7):1087-1093. Yusufaly TI, Zou J, Nelson TJ, Williamson CW, Simon A, Singhal M, Liu H, Wong H, Saenz CC, Mayadev J, McHale MT, Yashar CM, Eskander R, Sharabi A, Hoh CK, Obrzut S, Mell LK. PMID: 34711618; PMCID: PMC9258568.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening. Implement Sci Commun. 2021 Sep 23; 2(1):108. Hahn EE, Munoz-Plaza C, Altman DE, Hsu C, Cannizzaro NT, Ngo-Metzger Q, Wride P, Gould MK, Mittman BS, Hodeib M, Tewari KS, Ajamian LH, Eskander RN, Tewari D, Chao CR. PMID: 34556189; PMCID: PMC8461958.
      View in: PubMed   Mentions: 3  
    24. Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer. Gynecol Oncol. 2021 11; 163(2):299-304. Jou J, Charo L, Hom-Tedla M, Coakley K, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. PMID: 34561099.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial. Int J Radiat Oncol Biol Phys. 2022 01 01; 112(1):169-178. Williamson CW, Sirák I, Xu R, Portelance L, Wei L, Tarnawski R, Mahantshetty U, Heide ES, Yashar CM, McHale MT, Bosch W, Lowenstein J, Saenz CC, Plaxe S, Eskander R, Einck J, Mundt AJ, Mayadev J, Mell LK. PMID: 34419564; PMCID: PMC8688221.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    26. Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol. Am J Obstet Gynecol. 2021 10; 225(4):442.e1-442.e10. Melber DJ, Berman ZT, Jacobs MB, Picel AC, Conturie CL, Zhang-Rutledge K, Binder PS, Eskander RN, Roberts AC, McHale MT, Ramos GA, Ballas J, Kelly TF. PMID: 34245679.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials. Gynecol Oncol. 2021 08; 162(2):389-393. Jou J, Brodsky A, Charo L, Binder P, Saenz C, Eskander RN, McHale M, Plaxe S. PMID: 34099315.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer. JAMA Netw Open. 2021 06 01; 4(6):e2114162. Graf RP, Eskander R, Brueggeman L, Stupack DG. PMID: 34181012; PMCID: PMC8239953.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    29. Survey of trends in authorship assignment in gynecologic oncology: Keeping score and playing fair. Gynecol Oncol Rep. 2021 May; 36:100755. Chambers LM, Watson CH, Yao M, Levinson K, Alvarez RD, Eskander RN, Buechel M, Michener CM, Jernigan A. PMID: 33855146; PMCID: PMC8027688.
      View in: PubMed   Mentions: 1  
    30. Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials. Ther Adv Med Oncol. 2021; 13:17588359211001199. Eskander RN, Powell MA. PMID: 33796152; PMCID: PMC7970168.
      View in: PubMed   Mentions: 5  
    31. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. Gynecol Oncol. 2021 07; 162(1):203-209. Monk BJ, Coleman RL, Herzog TJ, Moore KN, O'Malley DM, Randall LM, Slomovitz BM, Eskander R, Pothuri B, Reese LL, Mannel RS, Copeland LJ. PMID: 33722417.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Maternal to fetal transmission of cancer: implications for molecular tumor testing, immune regulation, and pediatric malignancies. Med (N Y). 2021 03 12; 2(3):211-213. Eskander RN, Kurzrock R. PMID: 33855310; PMCID: PMC8040028.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    33. KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. Oncologist. 2021 04; 26(4):e530-e536. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R. PMID: 33528846; PMCID: PMC8018312.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiation. Gynecol Oncol. 2021 03; 160(3):721-728. Jou J, Coulter E, Roberts T, Binder P, Saenz C, McHale M, Plaxe S, Mayadev J, Eskander RN. PMID: 33342621.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. Clinical trials, adaptability and the COVID-19 pandemic. Gynecol Oncol Rep. 2021 Feb; 35:100680. Eskander RN, Pothuri B, Randall L, O'Malley D, Slomovitz B, Moore K, Coleman R, Herzog T, Monk BJ, Copeland L. PMID: 33319009; PMCID: PMC7723439.
      View in: PubMed   Mentions: 1  
    36. HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease. Gynecol Oncol. 2021 04; 161(1):25-33. Jou J, Zimmer Z, Charo L, Yau C, Saenz C, Eskander R, McHale M, Veerapong J, Plaxe S, Binder P. PMID: 33293046.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer. J Obstet Gynaecol. 2021 Aug; 41(6):956-961. Sanders BE, Saharti S, Laus K, Bristow RE, Eskander RN. PMID: 33228421.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Low-risk multivariate index assay scores, physician referral and surgical choices in women with adnexal masses. Curr Med Res Opin. 2020 12; 36(12):2079-2083. Dunton CJ, Eskander RN, Bullock RG, Pappas T. PMID: 33107342.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Charting a professional course for academic gynecologic oncology mentors. Gynecol Oncol. 2021 01; 160(1):265-270. Jou J, Binder P, Saenz C, Eskander R, McHale M, Plaxe S. PMID: 33131903.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    41. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States. Gynecol Oncol. 2020 12; 159(3):681-686. Charo LM, Jou J, Binder P, Hohmann SF, Saenz C, McHale M, Eskander RN, Plaxe S. PMID: 32977989.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    42. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021 01; 15(1):67-79. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280; PMCID: PMC7782073.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    43. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):396-412. Dyer BA, Feng CH, Eskander R, Sharabi AB, Mell LK, McHale M, Mayadev JS. PMID: 32942005.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    44. Relationship status and other demographic influences on survival in patients with ovarian cancer. Int J Gynecol Cancer. 2020 12; 30(12):1922-1927. Gardner AB, Sanders BE, Mann AK, Liao CI, Eskander RN, Kapp DS, Chan JK. PMID: 32920535.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. JCO Precis Oncol. 2020; 4. Eskander RN, Elvin J, Gay L, Ross JS, Miller VA, Kurzrock R. PMID: 33015532; PMCID: PMC7529537.
      View in: PubMed   Mentions: 16     Fields:    
    46. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. Gynecol Oncol. 2020 10; 159(1):8-12. Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D. PMID: 32778410.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How? Female Pelvic Med Reconstr Surg. 2020 06; 26(6):401-406. Catanzarite T, Eskander RN. PMID: 31135579.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):964-973. Mell LK, Xu R, Yashar CM, McHale MT, Einck JP, Mayadev J, Lee E, Binder P, Rash D, Eskander R, Heide ES, Plaxe SC, Mundt AJ, Saenz CC. PMID: 32334034; PMCID: PMC9440640.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    49. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584; PMCID: PMC7028323.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    50. Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial. Gynecol Oncol. 2020 05; 157(2):494-499. Charo LM, Vaida F, Eskander RN, Binder P, Saenz C, McHale M, Plaxe S. PMID: 32081462.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    51. Disseminated Endometriosis and Low-Grade Endometrioid Stromal Sarcoma in a Patient with a History of Uterine Morcellation for Adenomyosis. Case Rep Obstet Gynecol. 2020; 2020:7201930. Stefanko DP, Eskander R, Aisagbonhi O. PMID: 32089919; PMCID: PMC7025032.
      View in: PubMed   Mentions: 4  
    52. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2020 02; 156(2):423-429. Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M. PMID: 31843273; PMCID: PMC7103063.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    53. Moving beyond cytotoxic drug dosing in ovarian cancer. Lancet. 2019 12 07; 394(10214):2043-2045. Eskander RN, Monk BJ. PMID: 31791687.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    54. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes. Clin Exp Metastasis. 2020 02; 37(1):107-113. Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN, Chan JK. PMID: 31758289.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    55. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019 12 01; 25(23):7035-7045. Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI. PMID: 31383735.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    56. Dramatic response to Laetrile and cannabidiol (CBD) oil in a patient with metastatic low grade serous ovarian carcinoma. Gynecol Oncol Rep. 2019 Aug; 29:10-12. Barrie AM, Gushue AC, Eskander RN. PMID: 31193514; PMCID: PMC6535622.
      View in: PubMed   Mentions: 12  
    57. Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency. Cancer. 2019 02 01; 125(3):337-339. Eskander RN. PMID: 30561783.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    58. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:480-487. Eskander RN. PMID: 30231335.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    59. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530. Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. PMID: 29550184; PMCID: PMC7265815.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    60. PARP Inhibitors in Epithelial Ovarian Cancer. Recent Pat Anticancer Drug Discov. 2018; 13(2):145-158. Taylor KN, Eskander RN. PMID: 29205122.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    61. EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol Oncol Res Pract. 2017; 4:17. Alldredge JK, Eskander RN. PMID: 29093822; PMCID: PMC5663065.
      View in: PubMed   Mentions: 23  
    62. Primary low-grade endometrial stromal sarcoma of the omentum. Gynecol Oncol Rep. 2017 Aug; 21:119-121. Clair K, Wolford J, Veran-Taguibao S, Kim G, Eskander RN. PMID: 28831418; PMCID: PMC5554916.
      View in: PubMed   Mentions: 3  
    63. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract. 2017; 4:3. Paraghamian SE, Longoria TC, Eskander RN. PMID: 28174665; PMCID: PMC5290639.
      View in: PubMed   Mentions: 33  
    64. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. Curr Med Res Opin. 2016 06; 32(6):1161-5. Eskander RN, Carpenter BA, Wu HG, Wolf JK. PMID: 27052730.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2016; 3:2. Longoria TC, Eskander RN. PMID: 27232495; PMCID: PMC4881200.
      View in: PubMed   Mentions: 1  
    66. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32. Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. PMID: 26397159; PMCID: PMC5061499.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    67. Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015; 2:11. Longoria TC, Eskander RN. PMID: 27231571; PMCID: PMC4881063.
      View in: PubMed   Mentions: 24  
    68. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3829-35. Tewari KS, Eskander RN, Monk BJ. PMID: 26169965.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    69. Extensive Tattoos Mimicking Lymphatic Metastasis on Positron Emission Tomography Scan in a Patient With Cervical Cancer. Obstet Gynecol. 2015 Jul; 126(1):182-5. Grove N, Zheng M, Bristow RE, Eskander RN. PMID: 25923020.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    70. Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma. Mol Cancer. 2015 Apr 17; 14:86. Ji T, Guo Y, Kim K, McQueen P, Ghaffar S, Christ A, Lin C, Eskander R, Zi X, Hoang BH. PMID: 25890345; PMCID: PMC4411772.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    71. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol. 2015 Apr 10; 6(2):16-21. Cripe J, Eskander R, Tewari K. PMID: 25866706; PMCID: PMC4390890.
      View in: PubMed   Mentions: 8  
    72. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome. Gynecol Oncol Rep. 2015 Apr; 12:31-3. Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. PMID: 26076155; PMCID: PMC4442652.
      View in: PubMed   Mentions:
    73. Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer. Recent Pat Anticancer Drug Discov. 2015; 10(2):133-44. Longoria TC, Eskander RN. PMID: 25938471.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    74. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 01; 37(1):20-38. Eskander RN, Tewari KS. PMID: 25592089.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    75. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015; 11(6):909-22. Eskander RN, Tewari KS. PMID: 25760973; PMCID: PMC5613942.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population. J Clin Oncol. 2014 Dec 20; 32(36):4113-9. Eskander RN, Chang J, Ziogas A, Anton-Culver H, Bristow RE. PMID: 25385738; PMCID: PMC4517941.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    77. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014 Nov; 6(6):280-92. Eskander RN, Tewari KS. PMID: 25364393; PMCID: PMC4206649.
      View in: PubMed   Mentions: 15  
    78. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol. 2014 Nov; 7(6):847-58. Eskander RN, Tewari KS. PMID: 25301678.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    79. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Ann Surg Oncol. 2015 Feb; 22(2):655-61. Cripe J, Tseng J, Eskander R, Fader AN, Tanner E, Bristow R. PMID: 25155402.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    80. Can surgical management of bone metastases improve quality of life among women with gynecologic cancer? World J Surg Oncol. 2014 Aug 05; 12:250. Ji T, Eskander R, Wang Y, Sun K, Hoang BH, Guo W. PMID: 25091036; PMCID: PMC4125343.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    81. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014 Aug; 26(4):314-21. Eskander RN, Tewari KS. PMID: 24979076.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    82. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014 Jul; 25(3):249-59. Eskander RN, Tewari KS. PMID: 25045438; PMCID: PMC4102744.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    83. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):613-22. Eskander RN, Tewari KS. PMID: 24984781.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    84. Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review. World J Radiol. 2014 Jun 28; 6(6):366-73. Long B, Eskander RN, Tewari KS. PMID: 24976937; PMCID: PMC4072821.
      View in: PubMed   Mentions: 3  
    85. Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84. Eskander RN, Osann K, Dickson E, Holman LL, Rauh-Hain JA, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. PMID: 24887355; PMCID: PMC4191825.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    86. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise. Curr Treat Options Oncol. 2014 Mar; 15(1):27-40. Eskander RN, Cripe J, Bristow RE. PMID: 24338278.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    87. American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer. Int J Gynecol Cancer. 2014 Jan; 24(1):13-8. Eskander RN, Tewari KS. PMID: 24300468; PMCID: PMC3907666.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    88. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014 Feb; 132(2):496-505. Eskander RN, Tewari KS. PMID: 24316305.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    89. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013 Oct 03; 5(Suppl 1):55-61. Eskander RN, Tewari KS. PMID: 24124397; PMCID: PMC3795053.
      View in: PubMed   Mentions: 12  
    90. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 2013 Jul; 23(6):997-1005. Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B. PMID: 23792601; PMCID: PMC3694282.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    91. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer. 2013 Jun 10; 12:55. Ji T, Lin C, Krill LS, Eskander R, Guo Y, Zi X, Hoang BH. PMID: 23764122; PMCID: PMC3681603.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    92. Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol. 2013 May; 32(3):293-8. Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. PMID: 23518913.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    93. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013; 2013:147541. Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, Rooney K, Ji T, Eskander R, Zi X, Hoang BH. PMID: 23476112; PMCID: PMC3582188.
      View in: PubMed   Mentions: 31  
    94. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012; 4:395-404. Eskander RN, Tewari KS. PMID: 22927770; PMCID: PMC3422105.
      View in: PubMed   Mentions: 13  
    95. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug; 38(8):1086-94. Eskander RN, Randall LM, Sakai T, Guo Y, Hoang B, Zi X. PMID: 22540374; PMCID: PMC3405181.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    96. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecol Oncol. 2012 Aug; 126(2):259-67. Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ, Holcombe RF. PMID: 22555103; PMCID: PMC3688285.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    97. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res. 2012 Jul; 30(7):1045-50. Sakai T, Eskander RN, Guo Y, Kim KJ, Mefford J, Hopkins J, Bhatia NN, Zi X, Hoang BH. PMID: 22213202; PMCID: PMC3685290.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    98. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res. 2011 Nov; 37(11):1731-3. Eskander RN, Tarsa M, Herbst KD, Kelly TF. PMID: 21790885.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    99. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug; 205(2):103-10. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. PMID: 21411052; PMCID: PMC5111967.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    100. Bevacizumab in the treatment of ovarian cancer. Biologics. 2011; 5:1-5. Eskander RN, Randall LM. PMID: 21383911; PMCID: PMC3044789.
      View in: PubMed   Mentions: 15  
    101. Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy target and normal tissue contouring. Int J Gynecol Cancer. 2010 Jan; 20(1):47-53. Eskander RN, Scanderbeg D, Saenz CC, Brown M, Yashar C. PMID: 20130502.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    102. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol. 2010 Jan; 115(1):65-69. Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, Moore TR, Resnik R. PMID: 20027036.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    103. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):573-81. Warshak CR, Eskander R, Hull AD, Scioscia AL, Mattrey RF, Benirschke K, Resnik R. PMID: 16946217.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    Ramez's Networks
    Concepts (341)
    Derived automatically from this person's publications.
    Co-Authors (65)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department